Literature DB >> 24355193

Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.

N Knöpfel1, A Martín-Santiago2, A Bauza1, J A Hervás3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24355193     DOI： 10.1016/j.ad.2013.09.013

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN： 0001-7310


× No keyword cloud information.
  3 in total

1.  Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.

Authors:  Mary Kay Koenig; Cynthia S Bell; Adelaide A Hebert; Joan Roberson; Joshua A Samuels; John M Slopis; Patti Tate; Hope Northrup
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

Review 2.  Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.

Authors:  Michael A Cardis; Cynthia Marie Carver DeKlotz
Journal:  Arch Dis Child       Date:  2017-03-28       Impact factor: 3.791

3.  Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.

Authors:  Daniel Ebrahimi-Fakhari; Cornelia Sigrid Lissi Müller; Sascha Meyer; Marina Flotats-Bastardas; Thomas Vogt; Claudia Pföhler
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.